Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04457089 · ClinicalTrials.gov registry record · Early Phase 1
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
A Early Phase 1 study of Recurrent Ovarian Cancer and Platinum-sensitive Ovarian Cancer, sponsored by Marc Goodman.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04457089 is a Early Phase 1 study of Recurrent Ovarian Cancer and Platinum-sensitive Ovarian Cancer that has completed, run by Marc Goodman. The registered enrollment target is 18 participants, below the 188-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04457089, a Early Phase 1 study of Recurrent Ovarian Cancer and Platinum-sensitive Ovarian Cancer, has completed, sponsored by Marc Goodman.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.
Conditions Studied
Interventions
- DRUG Simvastatin 40mg
Study Locations (1)
California
- Cedars Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2025-05-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04457089
The ClinicalTrials.gov registry entry for NCT04457089 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Marc Goodman, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Simvastatin 40mg is the first listed.
NCT04457089 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04457089 about?
NCT04457089 is a clinical study titled "Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer". This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.
What is the current status of trial NCT04457089?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2021-01-25. Estimated completion is 2025-05-12.
What conditions does trial NCT04457089 study?
This clinical trial studies the following conditions: Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer.
What interventions are being tested in trial NCT04457089?
The interventions under investigation include: Simvastatin 40mg (DRUG).
Who is sponsoring clinical trial NCT04457089?
This trial is sponsored by Marc Goodman, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04457089 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RECRUITING · Phase 1
-
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
RECRUITING · Phase 2
-
Combination Therapy for Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Ovarian Cancer
All registered trials for this condition
Platinum-sensitive Ovarian Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.